On Wednesday, Shares of Laredo Petroleum Inc (NYSE:LPI), lost -5.99% to $7.85.
On Monday, December 28, 2015, Nasdaq Composite ended at 5,040.99, down 0.15%, Dow Jones Industrial Average declined 0.14%, to finish the day at 17,528.27, and the S&P 500 closed at 2,056.5, down 0.22%.
Laredo Petroleum Inc.’s stock edged lower by 5.80% to close Monday’s session at USD 8.28. The company’s shares oscillated between USD 7.74 and USD 8.53. The stock recorded a trading volume of 2.80 million shares, which was above its 50-day daily average volume of 2.76 million shares and below its 52-week average volume of 3.83 million shares. Over the last three days Laredo Petroleum Inc.’s shares have advanced 12.81% and in the past one week the stock has moved up 6.29%. Furthermore, over the last three months the stock has lost 8.41% and in the past six months the shares have shed 34.49%. The stock is trading at a price to book ratio of 1.73 which compares to a historical PB ratio of nearly 0.95. In addition to this, the stock of Laredo Petroleum Inc. is trading at a price to cash flow ratio of 4.82 and price to sales ratio of 2.61.
Laredo Petroleum, Inc. operates as an independent energy company in the United States. It focuses on the acquisition, exploration, and development of oil and natural gas properties primarily in the Permian Basin in west Texas.
Shares of Symantec Corporation (NASDAQ:SYMC), declined -0.37% to $21.29, during its last trading session.
Symantec Corp. (SYMC) and The Carlyle Group (CG), declared that they expect to close Carlyle’s acquisition of Veritas on January 29, 2016, subject to the satisfaction of customary closing conditions. The closing was formerly predictable to take place on January 1, 2016.
Bill Coleman, who will become CEO of Veritas upon the close of the transaction, said, “The team at Carlyle and I continue to be very excited about Veritas, its strong brand and products, in addition to its top-tier customer and partner base. We see in Veritas an incredible opportunity for value creation and look forward to working alongside the strong existing Veritas team.”
Symantec Corporation, together with its auxiliaries, provides security, backup, and availability solutions worldwide. Its products and services protect people and information in various environments from the mobile device and enterprise data center and to cloud-based systems.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with -1.05% loss, and closed at $5.65.
Exelixis, declared that it has accomplished the submission of its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cabozantinib as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy. Exelixis has requested Priority Review as part of the NDA filing.
In August 2015, the FDA granted Breakthrough Therapy designation to cabozantinib for this potential advanced RCC indication. Breakthrough Therapy designation can expedite the development and review of drugs that are intended to treat serious or life-threatening diseases, and for which preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically noteworthy endpoints. Drugs that receive Breakthrough Therapy designation may benefit from the involvement of FDA senior leadership in the review process, rolling submission, and other benefits. Before receiving Breakthrough Therapy designation, cabozantinib received Fast Track designation for its potential advanced RCC indication in April 2015.
“Concluding the submission of our rolling New Drug Application brings us closer to our aim of improving the treatment options for patients with advanced kidney cancer,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “Following the release of positive top-line results from our phase 3 pivotal trial in July, the Exelixis team worked expeditiously to complete the U.S. regulatory filing by year end. We look forward to ongoing to work with the FDA team during the review process.”
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
